AN2 Therapeutics, Inc.
ANTX
$1.07
-$0.06-5.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.31% | 20.72% | -1.71% | -19.06% | -35.79% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.23% | -9.82% | -17.74% | -2.75% | 5.89% |
| Change in Net Operating Assets | -254.73% | -151.34% | -151.18% | -117.60% | -72.16% |
| Cash from Operations | 28.67% | 7.56% | -39.20% | -46.46% | -54.73% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 234.50% | 226.14% | 264.41% | -185.73% | -12.12% |
| Cash from Investing | 234.50% | 226.14% | 264.41% | -185.73% | -12.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.90% | -99.56% | -99.56% | 245.03% | 1,058.53% |
| Repurchase of Common Stock | -- | -- | -- | -3,110.00% | -3,110.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.90% | -99.56% | -99.94% | 243.54% | 1,055.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -133.53% | 149.29% | -76.72% | -7,264.80% | 96.39% |